Prosonix Set to Become World Leaders in Added Value Ultrasonic Process Solutions
Prosonix Limited [Oxford UK] are delighted to announce the establishment of their new company on March 31st 2006.
The business will be led by new CEO David Hipkiss, with commercial operations directed by COO Andy Bush, and research, development and technology championed by CTO Dr Graham Ruecroft.
Prosonix vision is to become acknowledged world leaders in the commercialization of proprietary added value ultrasonic process solutions, and firmly intends to build upon the rapid growth and highly successful business development previously conducted under the C3 Technology brand.
Now based in new state-of-the-art facilities at the Oxford Science Park, Oxford UK, Prosonix teams of chemists and engineers work together to deliver a unique multidisciplinary approach to solving customers complex problems, leveraging proprietary intellectual property and patented bespoke sonoprocessing equipment for cost effective mutual advantage at commercial scale.
Prosonix technology can be applied at any stage during product development and is already proven across scale in a wide range of challenging industrial environments, and helps reduce time to market, enhance productivity, and improve product performance. Core markets include Pharmaceuticals and Minerals Processing, where Prosonix sonocrystallization technology is employed at commercial scale for the Complete Crystallization Control™ of customer’s products, processes and unit operations. Prosonix has rapidly evolving activities in the oil and gas markets, confectionary and bioprocessing. Prosonix have also established a number of strategic partnerships with a range of global leading academic institutions and technology partners that places Prosonix firmly at the cutting edge of the next generation of commercial scale ultrasonic process intensification solutions.
These include international award winning CrystalGEM™ predictive crystallization technology, new SAX™ nanocrystallization technology, and a brand new area of focus in Sonobiocatalysis™.
Commenting on the company establishment, CEO David Hipkiss said: “This is a major milestone for the Prosonix team after four years of hard work in taking a hitherto academic technology to commercial scale. We look forward to delivering on the full worldwide potential of the technology over the years to come and consolidating our acknowledged position as Experts in Sound Science™.”
Prosonix Shortlisted for Innovation Award at CPHI 2006
This international peer recognition
of the potential of SAXTM (Solution Atomization and Sonocrystallization) follows on from their CPhI Worldwide 2005
Innovation Award Gold Medal success for CrystalGEMTM, and confirms Prosonix’s status as an acknowledged world
leader in the commercialisation of cutting edge technology in pharmaceutical ultrasonic process chemistry.
For full details please review the press release
http://www.prosonix.co.uk/html/pressreleases.php
Prosonix presents at leading process conference
Presented at Process Chemistry & Engineering:Working Together in Isolation 10th – 12th April 2006, Newcastle, UK
Click here to download the presentation in PDF format (3.3)mb
Graham Ruecroft PhD explains the benefits that ultrasonics can bring to drug formulators in terms of improved yields and reaction times
Prosonix Wins Popular Vote At Technology Showcase
VentureFest 2006 Prosonix Elevator Speech
‘Good morning, my name is David Hipkiss and I am the CEO of Prosonix Limited, Experts in Sound Science and World Leaders in the Commercialisation of Added Value Ultrasonic Process Solutions.
A young and growing company, Prosonix successful licensing business model has delivered over 30 collaborations, 3 commercial scale equipment supply contracts, and 8 license agreements to date with revenues set to be a record this fiscal year ending March 2007.
Before Prosonix the use of ultrasound in chemistry was considered solely an academic curiosity, and its exploitation had been significantly curtailed because of perceived insurmountable engineering challenges. In a worlds first, Prosonix has overcome massive engineering hurdles and made that academic curiosity a commercial reality. We are only just beginning to realise the tremendous latent potential for industrial scale sonocrystallization, sonoprocessing, sonochemistry and the new field of sonobiocatalysis.
Our proprietary process and reactor technology harnesses the power of acoustic cavitation given by high intensity power ultrasound, and is already proven across scale and in a range of industrial environments, including high value mineral processing, the energy sector and pharmaceuticals.
In minerals processing, our technology has been in continuous use for the last 18 months at Europe’s largest alumina refinery and is helping to increase productivity of alumina production. Building on this success we have also recently concluded a global license deal with the worlds leading alumina supplier and will begin our global roll out later this summer.
In a new and exciting development in the energy sector, our technology has been proven to extend the life and operational efficiency of oil platforms with concurrent significant environmental benefits. We are now undertaking a rapid commercialisation program with a strategic partner. This application also has translational benefits in a number of different industry segments.
In pharmaceuticals where our main focus of activity lies, our particle engineering technology is helping peoples lives by enabling the cost effective production of new medicines, optimising the pharmaceutical R&D process using our award winning CrystalGEM technology, building in the latest Quality by Design philosophy from the FDA to bring right first time manufacturing to many pharmaceutical production processes. Additionally our newly in-licensed SAX nanocrystallization technology represents a paradigm shift in the ability to manufacture of a range of inhaled therapeutic molecules and enhancing the drug delivery potential of single and combination products.
Other significant opportunities exist in foods, environmental processing, specialty and performance chemicals, renewable energy sources to name but a few.
Finally our teams commercialisation success to date is evidenced by our customers success which are embodied in our collaborative development, equipment supply, and license deals, and moreover the trust which our innovation partners place in us to take our joint developments to market.
Simply put, if you want to win, work with us and grow with us.
Partner with Prosonix, the Experts in Sound Science.’
Prosonix Launch New SAXTM Technology
Prosonix Limited (Oxford, UK) is delighted to announce an agreement with the University of Bath (Bath, UK) for the exclusive commercialisation of the University’s unique sonocrystallization particle engineering technology Solution
Atomisation and Crystallization by Sonication (SAXTM). The agreement builds on 18 months of initial collaboration and technology evaluation between the parties.
Limitations of conventional crystallization techniques in the processing of pharmaceutical ingredients for a number of dosage forms typically requires the need for micronisation. These low-tech destructive based techniques are
expensive, unnecessary and can adversely affect a range of highly important physicochemical properties.
There is an unmet and pressing need to engineer crystalline particles with an even greater control of the surface characteristics and surface geometry of micron and sub-micron sized particles while maintaining high throughput, low
cost and industrial scalability.
Alternative processes for the production of drug particles within an optimum particle size range, for example by the use of supercritical fluids, have generated significant interest and potential, albeit with limited success to date. Recent industry announcements raise serious question marks about its scalability and cost effectiveness as the technique
requires extremes of pressure, only delivers minimal volume, and can lead to a high degree of amorphous content.
Discovered by Dr Robert Price from the University’s Department of Pharmacy and Pharmacology
(http://www.bath.ac.uk/pharmacy/home), SAXTM is a unique single step, solution-to-particle-technology, incorporating solution atomisation and sonocrystallization, that has shown significant potential benefits in the production of particles, particularly for inhaled therapeutics, but also has tremendous potential in production of nanosuspensions and
improved particles for other formulation techniques, including pharmaceutical co-crystals and combination based therapies. The technology allows the production in a well-defined particle size range as well as controlling the
macroscopic morphology, including polymorphism, and mesoscopic surface topography. Indeed these properties are invaluable in defining aerodynamic properties of particles, shelf life, stability, bioavailability and efficacy. To this end
SAXTM particles can have unique spherical shape and surface nanotopology providing minimum area for interfacial contact with low surface free energies.
Commenting, Prosonix CEO David Hipkiss said,
“We are delighted to have signed this agreement and be working in partnership with Dr Price and the University of Bath in this very exciting and strategically important area. We believe the SAXTM technology has world beating potential in allowing pharmaceutical companies to engineer particles ‘to order’ with the optimum crystal morphology, polymorph control and formulation performance. The area of inhaled therapeutics is particularly exciting, and SAXTM has a number of significant advantages over current approaches. It is a significant step in our overall goal to make commercially available an automated technology that allows ‘dial-a-particle’ philosophy to drug delivery.
Adding his approval, Dr Robert Price said,
“It is extremely exciting to be collaborating with Prosonix in developing the SAXTM technology for superior particle engineering of active pharmaceutical ingredients for inhaled therapeutics. Prosonix has tremendous experience, a unique track record and a world leadership position in developing and commercialising sonocrystallization processes and equipment in the pharmaceutical industry. I look forward to seeing SAXTM in commercial operation working
extensively with Prosonix in the years ahead.”
Prosonix and UCB Extend Co-Development Agreement
Prosonix Ltd (Oxford UK) and UCB SA (Braine l’Alleud, Belgium), are pleased to announce the extension of their Co-Development and Licensing Agreement for the utilization of Prosonix’ proprietary sonocrystallization technology across a range of its pharmaceutical products.
The renewal of the Agreement follows successful Proof of Concept, and Initial Proof of Process studies on two of UCB’s lead pharmaceutical products and represents the culmination of almost 3 years of collaborative research and development effort between the parties.
To enable further scale up and clinical development activities to be undertaken by UCB, Prosonix has provided a bespoke multipurpose ProsonitronTM sonocrystallization reactor system that will be utilized in the cGMP manufacturing facilities at UCB’s Braine l’Alleud site.
Prosonix sonocrystallization technology works by controlling and actively manipulating nucleation and subsequent crystal growth behaviour that is fundamental to the control of physical form and the improvement of a crystallization process. Customers benefit from the control of crystal habit, amorphous state, polymorphs, manipulation of crystal size distribution, and the prevention and reversal of troublesome agglomerations.
Additional value adding improvements in related product properties such as purity,
filtration rate and bulk density are capitalised at production scale. An attractive feature of the technology is its scale-out nature, such that it can be applied at any stage and at any time across a product pipeline from early laboratory studies through to full industrialization.
Commenting on the Agreement, David Hipkiss, CEO of Prosonix said:
“The Prosonix team are delighted to have extended this key agreement with UCB. With the high added
value nature of the products and stringent requirements for the control of all aspects of physical form, pharmaceuticals represent a natural and core market segment for Prosonix proprietary sonocrystallization technology. UCB’s reputation to be early adopters of innovative new technologies coupled to their willingness to see these through to filing and full commercial operation makes them an ideal partner. This
culture coupled to their process R&D and chemical engineering excellence will contribute substantially to our future collaborative success.”
Adding his comments, Dr John Surtees UCB’s Director, Chemical Process R&D said:
“The Prosonix technology has the potential to become an ideal cost effective solution to a range of common crystallization problems associated with the manufacture of our pharmaceutical products. It is simple to use
and retrofit, has no moving parts, and requires no chemical additives. We plan for it to be a key technology platform within UCB and look forward to working with the Prosonix team in the future”
Prosonix and UCB Press Release
Prosonix features in In-Pharmatechnologist
License Agreement for World Wide Exploitation of Technology
Prosonix Announce The Signing of a License Agreement For World Wide Exploitation
of Proprietary Sonocrystallization Technology
Prosonix Limited (Oxford, UK) announce the signing of a far reaching License Agreement for the commercial application of Prosonix’s proprietary C3 sonocrystallization technology at Alcoa’s alumina refineries worldwide.
Alcoa is the world’s largest manufacturer of alumina with a global capacity of almost 15 million tonnes per annum, operating 9 refineries on 5 continents.
The License Agreement represents the culmination of almost 18 months of testing and pilot trials both in Europe and at Alcoa’s Technical Centre in Kwinana Western Australia. It is the second such deal Prosonix has concluded with a major alumina player.
Alumina is principally manufactured using the common Bayer process and is employed at over 50 alumina refineries worldwide, with total production exceeding 60 million tonnes in 2005. Demand for alumina and related products shows continued growth over the long term. Cost effective solutions that can increase production from existing assets are therefore highly prized.
Prosonix will also provide Alcoa with bespoke ProsonitronTM sonocrystallization reactor systems to those locations where it is applicable, with the first such system expected to be operational in late 2006.
Importantly, being of a small footprint and consuming minimal power in its ability to achieve significant process and productivity benefits with minimal running costs, the Prosonix C3 sonocrystallization technology
meets all the requirements for sustainable development, a key industry driver in the 21st Century.
Commenting on the Agreement, David Hipkiss, CEO of Prosonix said:
“The Prosonix team are delighted to have signed this Agreement with Alcoa, the worlds foremost and leading alumina producer. It represents a significant milestone for us in the alumina market and develops further confidence in our technology and business model. Alcoa have proved to be an excellent partner with their willingness, commitment and vision to evaluate new technologies contributing substantially to our success. We look forward to working with them in the years ahead.”
Prosonix and SAX acknowledged for Particle Engineering by Major Pharma
For more information and to download the presentation from the BPC website click on the link below.
Title: Engineering Formulation-Ready Active Pharmaceutical Ingredients: Myth or Reality?
by Ivan Marziano
This statement does not reflect the opinion of Prosonix
Prosonix Appoints Development Project Engineer
Prosonix Acknowledged by RSC as SME Company of the Month
Prosonix are delighted to announce that they were chosen by the Royal Society of Chemistry to highlight their Ultrasonic Crystallization and Particle Engineering business to the organization and it members.
A company profile and detail on Prosonix can be found by accessing the link below.
RSC Company of the Month - February 2007
Bath and Prosonix Sign SAX Agreement
University of Bath and Prosonix Sign Agreement for World Beating SAX Particle Engineering Technology
The University of Bath (Bath, UK) and Prosonix Limited (Oxford, UK) are delighted to announce the signing of an exclusive agreement for the development and commercialisation of the University’s novel particle engineering technology Solution, Atomisation and Crystallization by Sonication (SAXTM).
Under the terms of the agreement the University has granted to Prosonix a world-wide licence to commercialise SAXTM in the field of pharmaceutical and fine chemicals, with further option arrangements on future potential fields of use. Fiscal terms include an upfront payment,
milestones, and royalties on commercial exploitation. Prosonix has further committed to investing in continued development to commercialise the technology, including supporting a PhD studentship at the University and working in partnership with the University to optimise the quality delivery of particle characterisation services for Prosonix customers.
Limitations of conventional crystallization techniques in the processing of pharmaceutical
ingredients for a number of dosage forms typically requires the need for micronisation.
These low-tech destructive based techniques are expensive, unnecessary and can adversely affect a range of highly important physicochemical properties.
There is an unmet and pressing need to engineer crystalline particles with an even greater control of the surface characteristics and surface geometry of micron and sub-micron sized particles while maintaining high throughput, low cost and industrial scalability.
Alternative processes for the production of drug particles within an optimum particle size range, for example by the use of supercritical fluids, have generated significant interest and potential,albeit with limited success to date. Recent industry announcements raise serious question marks about its scalability and cost effectiveness as the technique requires extremes of pressure, only delivers minimal volume, and being a precipitation process can lead to a high degree of amorphous content.
Discovered by Dr Robert Price from the University’s Department of Pharmacy and Pharmacology(http://www.bath.ac.uk/pharmacy), SAXTM is a unique single step, solution-to-particle-technology, incorporating solution atomisation and sonocrystallization, that has shown significant potential benefits in the production of particles, particularly for inhaled therapeutics, but also has tremendous potential in production of nanosuspensions and improved particles for other formulation techniques, including pharmaceutical co-crystals and combination based therapies.
The technology allows the production in a well-defined particle size range as well as controlling the macroscopic morphology, including polymorphism, and mesoscopic surface topography.Indeed these properties are invaluable in defining aerodynamic properties of particles, shelf life, stability,bioavailability and efficacy. To this end SAXTM particles can have unique spherical shape and surface nanotopology providing minimum area for interfacial contact with low surface free energies.
Commenting, Prosonix CEO David Hipkiss said,
“We are delighted to have signed this agreement and be working in partnership with Dr Price and the University of Bath in this very exciting and strategically important area. We believe the SAXTM technology has world beating potential in allowing pharmaceutical companies to engineer particles ‘to order’ with the optimum crystal morphology, polymorph control and formulation performance. The area of inhaled therapeutics is particularly exciting, and SAXTM has a number of significant advantages over current approaches. It is a significant step in our overall goal to make commercially available an automated technology that allows ‘dial-a-particle’ philosophy to drug delivery. Our initial marketing efforts have already demonstrated a significant market pull for the approach from major innovator and generic pharmaceutical companies. We look forward to building our current two year relationship with the University into one of significant and long term value and mutual benefit.”
Malcolm Cross, Director of Research and Innovation Services, University of Bath further
agreed:
“This partnership with Prosonix offers an exciting opportunity to take a technology developed by academics at the University of Bath from the laboratory into the marketplace. It builds upon the previous track record of commercialisation enjoyed by the Department of Pharmacy and Pharmacology, and adds to the growing portfolio of business opportunities being successfully progressed and realised by Research and Innovation Services”.
Adding his approval, Dr Robert Price said,
“It is extremely exciting to be collaborating with Prosonix in developing the SAXTM technology for superior particle engineering of active pharmaceutical ingredients for inhaled therapeutics. Prosonix has tremendous experience, a unique track record and a world leadership position in developing and commercialising sonocrystallization processes and equipment in the pharmaceutical industry. I look forward to seeing SAXTM in commercial operation working extensively with Prosonix in the years ahead.”
Prosonix U.S. Launch at Informex 2007
Informex Exhibitor Showcase Presentation
Prosonix U.S. Launch at Informex 2007
Informex Exhibitor Showcase Presentation
Prosonix Shortlisted for RSC Team Innovation Award 2006
The Teamwork in Innovation Award is given to acknowledge collaborative projects in industry and academia that have lead to significant innovations in the chemical sciences.
Applications must have an industry element and be across companies or between industry and academia. Any size of team and any aspect of chemistry is welcomed.
Examples might be:
Innovation and development of a new chemistry-based product or process
Overcoming of a specific synthesis hurdle
Obtaining a substantial yield improvement by a novel technique
Demonstrating a significant economic or environmental benefit by reducing waste by-product or energy consumption
Pfizer Highlight SAX as Novel Method for Producing Respirable Particles
Dr Ivan Marziano of Pfizer Ltd., Sandwhich, UK presented on Novel Methodologies for Producing Respirable Particles and highlighted the SAXTM Technology as a key method that should be reviewed by Pharmaceutical companies in order to obtain 100% Crystalline Particles suitable for respiratory delivery.
Dr Marziano gave the presentaion at the APS Inhalation 2007 Conference at The University of Bath which was widely attended by worldwide representatives of the Pharmaceutical community.
This acknowledgement builds on a previous presentation at the British Pharmaceutical Conference and Exhibition 2006 by the Pfizer Crystallization Engineering Group Leader.
The presentation reviewed the current approaches to Particle Engineering and covered all aspects that could avoid Milling and Micronising, concluding with the SAX technology under the descriptor 'Droplet to Particle' technology.
Ultrasonic crystallization was also mentioned and the benefits Pfizer believed were associated with this technology.
The SAX technology was then described in depth by Dr Rob Price in the afternoon presentations.
Academy of Pharmaceutical Sciences
Prosonix and University of Bath Win Royal Society of Chemistry Innovation Award
Prosonix were presented with the Award at an Award's Ceremony held at Burlington House the RSC's Headquarters in London. They were delighted to have been chosen and for the technology to have been recognised by Europes Largest Professional Organisation for Advancing the Chemical Sciences.
For more information please see Poster Application Press Release and also The RSC Innovation Award
Prosonix wins award for SAX - 'Article In-PharmaTechnologist'
Prosonix and Bath University in the UK have won the Royal Society of Chemistry's (RSC) Innovation award for the development of a tool that enables the manufacture of crystalline pharmaceuticals of specific sizes.
The Solution Atomisation and Crystallization by Sonication (SAX ) technology uses an atomisation step that turns a solution into an aerosol before evaporation and sonication deliver discrete crystalline particles with tightly controlled size parameters.
"The award gives us an opportunity to get the technology into peoples minds - we have had lots of response since winning it," said Dr Graham Ruecroft, chief technical officer at Prosonix.
The therapeutic performance of the active pharmaceutical ingredients (APIs) used in drug formulations are often affected by their solid state forms.
Current approaches for API preparation are via molecule to crystal, crystal to particle and particle to dosage form strategy.
"Typically the pharmaceutical industry makes large crystals before milling them into smaller particles, this is an age old technique that gives inconsistent results," said Ruecroft.
This inconsistency can be problematic when making drugs for inhalation where a particle's aerodynamic profile plays a crucial part in its ability to reach the depths of the lung.
"The US Food and Drug Administration is pushing the consistency issue and saying that manufacturers must use reproducible techniques," he continued.
According to Ruecroft, the technique works by first atomising a concentrated solution of the API into an aerosol with a defined droplet size - typically between 5 and 10µm.
These droplets then undergo very careful evaporation to form viscous droplets that are heavily supersaturated.
As the droplets are spherical this shape is transferred to the particles that form inside the droplets.
They then make contact with a solvent in which the compounds are not soluble and the droplet is collapsed by ultrasonic waves to form unique spherical particles as small as 1 µm.
"Most of our work has far concentrated on small molecule drugs, such as small peptides with a weight of about 700 or 800 Daltons but we feel that sonocrystallisation could be used for larger biological drugs," said Ruecroft.
Historically, Prosonix has supplied technologies to customers to enable them to crystallise their products more efficiently.
However, Ruecroft said: "SAX is rather different, and we envisage that we will move to manufacturing products for people, by bringing in their primary manufactured product and turning it into the final API."
Prosonix Present at ChemSpec 2007
Full details and abstract can be found via the link below.
Prosonix Featured in 'Chemistry Today' publication
Abstract
Power ultrasound within chemical processing has
particular importance in crystallization control including nucleation, particle size distribution down to micron-size and morphology.
Microcrystalline drug particles for inhalation can also be prepared using new power ultrasound assisted technologies such as the Solution Atomisation and Crystallization by Sonification (SAX)technology being developed by Prosonix in conjunction with Rob Price of the University of Bath. This allows the production of spherical drug particles with superior geometrical, surface and performance properties.
For further info please follow link or read in our Download section
Prosonix Featured in 'Speciality Chemicals' publication
Abstract
It has been known for 80 years that power ultrasound,typically in the frequency range of 20-100 kHz, can have interesting effects on chemical and biochemical process systems, as well as influencing events in the crystallisation of organic and inorganic materials.
In the past, the absence of scale-up equipment,
led to some intransigence about using it. However,
the last 15 years or so have seen intensification in activity as technologists have become increasingly attracted to ultrasound’s potential and useful scaleup equipment has become available.
The equipment must be robust, effective and
approved for use in manufacturing areas where
flammable solvents are in use. Recent advances in
equipment have made its implementation at industrial scale feasible. There is now a lot of interest in the application of ultrasound to crystallisation - so called sonocrystallisation - and particle engineering in the pharmaceuticals and fine chemicals sectors.
For more details please visit our download section.
RSC Conference - Ultrasound in Synthesis, Particle Design and Measurement
The RSC SonoChemistry Group and The Formulation Science and Technology Group are jointly holding the Conference 'Molecules to Particles - The Use of Ultrasound in Synthesis, Particle Design and Measurement' on 15/16 January 2008 at Weetwood Hall, Leeds with key speakers from around the World from Academia and the Pharmaceutical Industry including Prof. Tim Mason, Prof. Giancarlo Cravotto, Dr Rob Price, Prof. Kevin Roberts, Prof. Malcolm Povey, Prof. Richard Challis, Prosonix, Pfizer and Merck & Co.Inc. For further details please follow the link.
To download conference details click here
Prosonix Ltd Completes Ł5M Funding Round
New investors in the round were led by Solon Ventures LP, advised by Solon Ventures Ltd (London, UK), joined by The Entrepreneurs Fund BV (Amsterdam, Netherlands) and Quest for Growth (Leuven, Belgium), and supported by the existing Investors.
Prosonix were advised by FirstCapital (London, UK).
Commenting on the deal, Prosonix CEO David Hipkiss said,
“Today is a very significant milestone in Prosonix’s development. Following the funding Prosonix will have a very strong balance sheet from which we will be able to accelerate our growth plans to build an exciting and long term profitable business serving our customers in the worldwide pharmaceutical and chemical industries.”
“In particular I would like to welcome our new Investors to the Prosonix team. I am certain that their proven expertise in successfully developing emerging life science and technology enterprises, will be invaluable in ensuring the future success of the business.”
Adding his approval, Solon Ventures Managing Director Angus Whiteley said,
“Prosonix and its team, led by David Hipkiss, have demonstrated that it has world-leading particle engineering capabilities. With this new capital Prosonix is well placed to expand these capabilities in support of their existing and fast growing customer base. Having confirmed its potential in a range of customer applications, we believe that the commercial scale use of the Prosonix sonocrystallization technology has the clear potential to become the crystallization technology of choice. We are excited to be able to assist David and his team at Prosonix in expanding its application in the pharmaceutical and chemical industries.”
Prosonix have decided this year instead of ditributing Christmas Cards to donate the money that would have been spent to a local Oxford Charity. Prosonix wish all of our customers and contacts a Very Merry Christmas and a Successful and Prosperous New Year!
Prosonix concludes worldwide exclusive license for Novel Ultrasonic Particle Eng
The license deal is the culmination of almost 18 months of collaboration and discussion between Prosonix and Rafael, and follows successful demonstration and enhancement of the Rafael process technology on a range of active pharmaceutical ingredients and key excipients using Prosonix proprietary ProsonitronTM ultrasonic reactors.
Importantly the Rafael process patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging.
Used in combination, the Rafael process technology and the proven Prosonix ProsonitronTM process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems, and overcomes many of the problems hitherto associated with classical dry milling or micronisation.
The license deal is the culmination of almost 18 months of collaboration and discussion between Prosonix and Rafael, and follows successful demonstration and enhancement of the Rafael process technology on a range of active pharmaceutical ingredients and key excipients using Prosonix proprietary ProsonitronTM ultrasonic reactors.
Importantly the Rafael process patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging.
Used in combination, the Rafael process technology and the proven Prosonix ProsonitronTM process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems, and overcomes many of the problems hitherto associated with classical dry milling or micronisation.
Prosonix Appoints Dr Jim Phillips as Non-Executive Chairman
Prosonix (Oxford, UK) leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, are delighted to announce the appointment of Dr Jim Phillips to the key post of Non-Executive Chairman.
Jim has over 20 years healthcare industry experience and is also a qualified physician with an MBA from Cass Business School, having extensive first hand experience in business development in pharmaceuticals, and in developing early stage ventures.
He has worked for Johnson & Johnson, and Novartis in Senior Executive roles, and was Founder & Chief Executive officer of Talisker Pharmaceuticals Ltd, which was acquired by EUSA Pharma Inc in July 2006 giving investors a successful exit.
As Chief Executive, Jim also took Bone Medical Ltd through its oversubscribed IPO in Australia in 2004. In addition he has held a number of other international board level roles including organizations such as West Sussex Health Authority, Lifegard Technologies Ltd, CRF Inc, Diabetology Ltd, EUSA Pharma Inc, OPi S.A.
Commenting on his appointment David Hipkiss, Prosonix CEO said
“I am delighted for Prosonix to have been able to have secured the services of Jim to accelerate us through our next stage of corporate development. He is an outstanding and key recruit with a proven track record of sustainable value generation in the life science sector.”
Adding his approval Dr Phillips said,
“Prosonix have demonstrated that it has world-leading particle engineering capabilities which have particular utility in the pharmaceutical life science sector. I am looking forward to be able to assist David and his team at Prosonix in expanding its application in the pharmaceutical and chemical industries, and generating long term value for our stakeholders and customers alike.”
Prosonix Your Inhalation Partner